{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:11:32Z","timestamp":1780715492418,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ejmech.2025.117284","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:07:45Z","timestamp":1736986065000},"page":"117284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of imidazolidinone derivatives as potent PPAR\u03b1\/\u03b4 agonists for the treatment of cholestatic liver diseases"],"prefix":"10.1016","volume":"286","author":[{"given":"Zhuoxin","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufan","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengqin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0172-4759","authenticated-orcid":false,"given":"Liang","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqi","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117284_bib1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s40265-021-01545-7","article-title":"Cholestatic liver disease: current treatment strategies and new therapeutic agents","volume":"81","author":"Hasegawa","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117284_bib2","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/hep.28965","article-title":"The ascending pathophysiology of cholestatic liver disease","volume":"65","author":"Jansen","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2025.117284_bib3","article-title":"Cholestatic liver diseases, Clin. Liver","volume":"17","author":"Levy","year":"2013","journal-title":"Dis."},{"key":"10.1016\/j.ejmech.2025.117284_bib4","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000179","article-title":"Primary biliary cholangitis: epidemiology prognosis and treatment","volume":"7","author":"Trivella","year":"2023","journal-title":"Hepatol. Commun."},{"key":"10.1016\/j.ejmech.2025.117284_bib5","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","article-title":"Primary sclerosing cholangitis - a comprehensive review","volume":"67","author":"Karlsen","year":"2017","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejmech.2025.117284_bib6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.32074\/1591-951X-245","article-title":"Autoimmune biliary diseases: primary biliary cholangitis and primary sclerosing cholangitis","volume":"113","author":"Sarcognato","year":"2021","journal-title":"Pathologica"},{"key":"10.1016\/j.ejmech.2025.117284_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1586\/17512433.2015.1092381","article-title":"Obeticholic acid for the treatment of primary biliary cirrhosis","volume":"9","author":"Trivedi","year":"2016","journal-title":"Expet Rev. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117284_bib8","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s40265-024-02075-8","article-title":"Elafibranor: first approval","volume":"84","author":"Blair","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117284_bib9","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s40265-024-02114-4","article-title":"Seladelpar: first approval","volume":"84","author":"Hoy","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.117284_bib10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/35013000","article-title":"Roles of PPARs in health and disease","volume":"405","author":"Kersten","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.117284_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.tips.2023.11.004","article-title":"PPAR agonists for the treatment of neuroinflammatory diseases","volume":"45","author":"Titus","year":"2024","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.117284_bib12","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","article-title":"PPAR control of metabolism and cardiovascular functions","volume":"18","author":"Montaigne","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejmech.2025.117284_bib13","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1021\/jm101360s","article-title":"Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators","volume":"55","author":"Pirat","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117284_bib14","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2019.01.067","article-title":"Role of PPAR receptor in different diseases and their ligands: physiological importance and clinical implications","volume":"15","author":"Mirza","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117284_bib15","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0022-2275(20)32398-1","article-title":"Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription","volume":"41","author":"Marrapodi","year":"2000","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejmech.2025.117284_bib16","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.26018","article-title":"Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid","volume":"57","author":"Honda","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2025.117284_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102056","article-title":"Selective PPAR\u03b4 agonist seladelpar suppresses bile acid synthesis by reducing hepatocyte CYP7A1 via the fibroblast growth factor 21 signaling pathway","volume":"298","author":"Kouno","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.117284_bib18","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1021\/acs.jmedchem.1c02002","article-title":"Design, synthesis, and biological evaluation of triazolone derivatives as potent PPAR\u03b1\/\u03b4 dual agonists for the treatment of nonalcoholic steatohepatitis","volume":"65","author":"Feng","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117284_bib19","doi-asserted-by":"crossref","first-page":"7331","DOI":"10.1021\/acs.jmedchem.2c02123","article-title":"Discovery of the first subnanomolar PPAR\u03b1\/\u03b4 dual agonist for the treatment of cholestatic liver diseases","volume":"66","author":"Feng","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117284_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2020.101727","article-title":"PPAR\u03b1 ligand-binding domain structures with endogenous fatty acids and fibrates","volume":"23","author":"Kamata","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.ejmech.2025.117284_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/612089","article-title":"Peroxisome proliferator-activated receptor alpha target genes","volume":"2010","author":"Rakhshandehroo","year":"2010","journal-title":"PPAR Res."},{"key":"10.1016\/j.ejmech.2025.117284_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116594","article-title":"Molecular insights into experimental models and therapeutics for cholestasis","volume":"174","author":"Zhang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.117284_bib23","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2353\/ajpath.2006.050404","article-title":"Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice","volume":"168","author":"Fickert","year":"2006","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ejmech.2025.117284_bib24","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.bbadis.2017.06.027","article-title":"Animal models of biliary injury and altered bile acid metabolism","volume":"1864","author":"Mariotti","year":"2018","journal-title":"Biochim. Biophys. Acta, Mol. Basis Dis."},{"key":"10.1016\/j.ejmech.2025.117284_bib25","article-title":"Integrated lipidomics and metabolomics study of four chemically induced mouse models of acute intrahepatic cholestasis","volume":"8","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117284_bib26","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1021\/acs.jcim.9b00838","article-title":"Discovery of novel peroxisome proliferator-activated receptor \u03b1 (PPAR\u03b1) agonists by virtual screening and biological evaluation","volume":"60","author":"Dai","year":"2020","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2025.117284_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116344","article-title":"Design, synthesis, and biological evaluation of piperazine derivatives as pan-PPARs agonists for the treatment of liver fibrosis","volume":"269","author":"Sun","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117284_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114800","article-title":"Discovery of novel AdipoRon analogues as potent anti-inflammatory agents against nonalcoholic steatohepatitis","volume":"244","author":"Dai","year":"2022","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425000492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425000492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T10:04:20Z","timestamp":1740391460000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425000492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":28,"alternative-id":["S0223523425000492"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117284","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of imidazolidinone derivatives as potent PPAR\u03b1\/\u03b4 agonists for the treatment of cholestatic liver diseases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117284","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117284"}}